At what enterprise value was VIVALTO SANTÉ acquired in 2021?

During the acquisition of VIVALTO SANTÉ by VIVALTO PARTNERS / IK PARTNERS / MACSF / ARKEA CAPITAL / BNP PARIBAS DEVELOPPEMENT in 2021, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of VIVALTO SANTÉ when it was acquired by VIVALTO PARTNERS / IK PARTNERS / MACSF / ARKEA CAPITAL / BNP PARIBAS DEVELOPPEMENT?

The estimated EV/EBITDA multiple for VIVALTO SANTÉ is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

What was the revenue of VIVALTO SANTÉ at the time of the deal?

The revenue of VIVALTO SANTÉ at the time of the deal is estimated to be in the range of 750M - 1.3b EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of VIVALTO SANTÉ during the acquisition?

VIVALTO SANTÉ's EBITDA is estimated to be in the range of 100M - 200M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the VIVALTO SANTÉ acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the VIVALTO SANTÉ deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/le-nouveau-tour-de-table-de-vivalto-sante-est-en-place-1369518

← DATABASE

Home Database Healthcare & PharmaVIVALTO SANTÉ

12/2021

VIVALTO SANTÉ acquired by VIVALTO PARTNERS, IK PARTNERS, MACSF, ARKEA CAPITAL & BNP PARIBAS DEVELOPPEMENT

FRANCE Health Providers / Healthcare Facilities / Clinics / Hospitals EV 1b - 4b EUR

Context

Vivalto Santé completed its third LBO, with Vivalto Partners — Daniel Caille's newly created investment management vehicle — taking control of the group. IK Partners joined as a key new minority shareholder alongside a broad consortium of reinvesting French institutional investors and the Bpifrance-Mubadala sovereign duo. The transaction is notably characterised by a strong medical and employee shareholder component, with approximately 1,000 physicians and ultimately 35% of employees targeted as co-investors. The financing structure comprises a Term Loan B and a revolving credit facility, supplemented by subordinated instruments arranged by Hayfin.

The company previously completed an external growth operation by acquiring Mathilde MéDical DéVeloppement in 2020.

VIVALTO SANTÉ, which reported an EBITDA margin of LOGIN in 2021, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Vivalto Santé is a leading French private hospital and clinic group, founded in 2009 by Daniel Caille and a group of physicians, operating under a distinctive "third way" governance model that associates medical professionals and financial investors under a shared ownership and decision-making structure. The group has grown rapidly through an active acquisition strategy.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2021

2020

Other operations with VIVALTO SANTÉ

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
01/2020	VIVALTO SANTÉ	MATHILDE MÉDICAL DÉVELOPPEMENT	FRANCE	Health Providers	Vivalto Santé acquired Mathilde Médical Développement, adding four establishments — two clinics and two radiotherapy centres — to its existing Normandie footprint. The acquisition complements Vivalto Santé's existing presence in the region through the Clinique de l'Europe in Rouen and the Hôpital Pasteur in Evreux. The deal follows a series of acquisitions completed in 2019, including the Hôpital Privé du Confluent in Nantes, the Polyclinique de l'Europe in Saint-Nazaire, and the Polyclinique du Parc in Cholet, reflecting Vivalto Santé's ongoing buy-and-build strategy across the French private hospital market.

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 750M - 1.3b EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of VIVALTO SANTÉ by VIVALTO PARTNERS / IK PARTNERS / MACSF / ARKEA CAPITAL / BNP PARIBAS DEVELOPPEMENT are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: vivalto santé

Acquirer: vivalto partners / ik partners / bnp paribas developpement / macsf / arkea capital